ArticleCurrent medicinal chemistry2026
Potential of HSP90AA1 as Diagnostic, Prognostic, and Immunological Biomarkers in Human Cancer Demonstrated through Pan-Cancer Investigation: A Bioinformatics Analysis.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionThe HSP90AA1 gene has been linked to a number of malignancies, but its precise function is still unknown, and no research has examined the connection between HSP90AA1 and pan-cancer. Therefore, further investigation into the relationship between HSP90AA1 and pan-cancer is required.
methodsWe utilized the human protein atlas (HPA) to analyze HSP90AA1 mRNA and protein expression levels in human organs, tissues, and cell lines. Subsequently, the 33 different cancer types' levels of HSP90AA1 mRNA expression were assessed, and a range of tumor types had their diagnostic and prognostic values assessed. Additionally, the regions with the most prevalent HSP90AA1 mutation types were found. HSP90AA1's PPI and miRNA regulatory networks were established, and its activating or inhibiting effects in established pathways were examined. Finally, we looked at the connection between immune cell and regulator infiltration levels in various cancers and the expression levels of HSP90AA1.
resultsThe nasopharynx, testis, fallopian tube, bronchus, duodenum, gallbladder, and epididymis are the primary organs that express the HSP90AA1 protein. Thirty-three cancers have elevated HSP90AA1 mRNA expression as compared to normal tissues. The most prevalent HSP90AA1 mutation location is X585. Analysis of HSP90AA1 as a diagnostic marker in pan-cancer showed that the good diagnostic utility of HSP90AA1 in a range of cancer types. High HSP90AA1 expression groups had poorer prognosis and were associated with clinical parameters. GO/KEGG and GSEA analyses showed that HSP90AA1 was mostly associated with pathways that are linked to tumor molecules and the immune system. HSP90AA1 was associated with immune cells and regulatory factors in various cancers. DISCUSSION: HSP90AA1 plays a role in immune microenvironment modulation in a range of tumor types and is correlated with prognosis. We hope to further validate the role of HSP90AA1 in tumors through cellular and functional assays, so as to achieve the validation of the theory, basic experiments, and clinical applications, and thus promote it as a recognized prognostic marker. And the development of corresponding targeted drugs for the HSP90AA1 locus may become a major challenging direction for future development.
conclusionHSP90AA1 was mostly associated with pathways that are linked to tumor molecules and the immune system, and was considered a potential diagnostic, prognostic, and immunological biomarker in human cancer.
Indexed as
Identifiers
41863160What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.